IGF-1 LR3 Research Peptide COA | Direct Peptides
Need help? Text us and our team of experts will reply in minutes
+1 (401) 684-4683
IGF-1 LR3 Research Peptide COA — research peptide image

IGF-1 LR3

CAS #: 946870-92-4

Size

1mg

5mg

Quantity

Single Vial

Pack of 10

IGF-1 LR3

Order Now, Ships Today

$79.00

One-time

Add To Cart

Research Use Only

All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.

Purity, ID, Quantity
Endotoxin

1mg

Certificate of Analysis

Third-party tested for 99% purity, ID, quantity.

View all

IGF-1 LR3 Overview

IGF-1 LR3 is an 83-amino acid synthetic polypeptide engineered to overcome limitations of native IGF-1 through two strategic modifications: glutamic acid-to-arginine substitution at position 3 and addition of a 13-residue N-terminal extension (MFPAMPLSSLFVN). These alterations reduce binding affinity for IGFBPs by approximately 100-fold while maintaining full target receptor activation capacity, resulting in increased bioavailability and extended half-life compared to native IGF-1. Research models examine its activation of tyrosine kinase signaling, downstream PI3K-Akt and Ras-MAPK pathways, effects on substrate uptake in experimental models, protein synthesis stimulation, and molecular proliferation in laboratory settings.

Francis et al. (1992). Castellino et al. (1992).

History

IGF-1 LR3 was developed in the early 1990s by researchers seeking to create a more stable and bioavailable form of IGF-1 for experimental applications. The modifications were first characterized by Francis, Ross, and colleagues at GroPep Bioreagents, who demonstrated that the arginine substitution and N-terminal extension dramatically reduced IGFBP binding while preserving IGF-1 receptor affinity. This engineered analog enabled more consistent experimental outcomes by circumventing the regulatory constraints imposed by binding proteins in biological systems.

Francis et al. (1992).

Research Findings

IGF-1 LR3 has been extensively studied in molecular signaling and pathway research, with investigations focusing on receptor-mediated signaling cascades, anabolic dynamics, substrate utilization, and molecular remodeling in various experimental models. Studies examine both its enhanced pharmacokinetic properties and downstream molecular responses.

Key Areas of Research:

  • Signaling: PI3K-Akt, MAPK-ERK, tyrosine kinase

  • Substrate: Uptake dynamics, lipid pathways, amino acid

  • Anabolic: Protein synthesis, proliferation, nitrogen

  • Molecular: Differentiation, survival signaling, viability

Together, these investigations demonstrate IGF-1 LR3's potent activation of signaling pathways. As a modified IGF-1 analog with reduced IGFBP binding, LR3 provides a research framework for examining target receptor biology, anabolic signaling mechanisms, and downstream pathway characterization in diverse experimental systems.

Francis et al., Journal of Molecular Endocrinology, 1992

Castellino et al., Biochemical and Biophysical Research Communications, 1992

Lu et al., Protein Expression and Purication, 2009

References

Francis G.L. et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3):213-223.

Castellino F.J. et al. (1992). Receptor binding and mitogenic potency of insulin-like growth factor I analogues modied at position 3. Biochemical and Biophysical Research Communications, 189(3):1641-1648.

Lu Z. et al. (2009). Expression and purification of recombinant human long-R3 insulin-like growth factor-I in Pichia pastoris. Protein Expression and Purification, 67(1):38-43.

IGF-1 LR3

Single Vial

Pack of 10

Order Now, Ships Today

1mg

$79.00

One-time

Our Process

View Products

IGF-1 LR3 Research Peptide COA — research peptide image

STEP 1

Precision Lyophilization

Manufactured in a controlled U.S. facility under strict compounding standards.

IGF-1 LR3 Research Peptide COA — research peptide image

STEP 2

Verified Purity

Every batch third-party tested with HPLC and mass spectrometry.

IGF-1 LR3 Research Peptide COA — research peptide image

STEP 3

Same-Day Fulfillment

Orders dispatched same-day from our U.S. facility.

Text us, our dedicated team is here to help

Reach out and get a response within minutes.

Text Us

IGF-1 LR3 Research Peptide COA — research peptide image

Frequently Asked Questions

Everything you need to know about our products and processes.

View Products

What's the actual amount in each vial?

Are additional supplies needed?

How long does a vial last?

Does the product come with instructions?

What purity level is guaranteed?

How should I store these products?

IGF-1 LR3 Research Peptide COA — research peptide image

Verified compounds.
Ready to ship.

Need help? Text us, and a team member will reply in minutes.

+1 (401) 684-4683

sales@directpeptid.com

© DirectPeptides 2026. All rights reserved.

Privacy Policy

Terms of Service

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.

Direct Peptides is a chemical supplier. Direct Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Direct Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.

All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption.